Sidoti & Co. initiates coverage on BioClinica (Nasdaq: BIOC) with a 'Buy' rating.

To ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE